{"id":"arq-501","safety":{"commonSideEffects":[{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ALK inhibitors, such as ARQ 501, target the ALK protein, which is involved in the development and progression of certain types of cancer. By inhibiting ALK, ARQ 501 aims to slow or stop the growth of cancer cells.","oneSentence":"ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:20.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with ALK rearrangement"}]},"trialDetails":[{"nctId":"NCT02514031","phase":"PHASE1","title":"ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-03-24","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT01502800","phase":"PHASE1","title":"Clinical Trial of ARQ 761 in Advanced Solid Tumors","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-12-29","conditions":"Solid Tumors","enrollment":91},{"nctId":"NCT03575078","phase":"PHASE1","title":"ARQ761 + PARP Inhibitor in Refractory Solid Tumors","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-06-25","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01285388","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2010-07","conditions":"Metabolic Syndrome, Obesity","enrollment":50},{"nctId":"NCT02029586","phase":"PHASE2","title":"Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis","status":"TERMINATED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2013-01","conditions":"Nonalcoholic Fatty Liver Disease","enrollment":18},{"nctId":"NCT02338856","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2015-01","conditions":"Metabolic Syndrome","enrollment":11},{"nctId":"NCT01444677","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2011-04","conditions":"Metabolic Syndrome, Obesity","enrollment":40},{"nctId":"NCT00622063","phase":"PHASE1, PHASE2","title":"An Extension Study for Patients Previously Treated With ARQ 501","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2006-12","conditions":"Cancer","enrollment":1},{"nctId":"NCT00524524","phase":"PHASE1","title":"An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2007-08","conditions":"Advanced Solid Tumors","enrollment":9},{"nctId":"NCT00310518","phase":"PHASE2","title":"Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2006-02","conditions":"Cancer","enrollment":30},{"nctId":"NCT00102700","phase":"PHASE2","title":"ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2005-01","conditions":"Pancreatic Cancer, Adenocarcinoma","enrollment":66},{"nctId":"NCT00075933","phase":"PHASE1","title":"ARQ 501 in Subjects With Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2003-09","conditions":"Cancer","enrollment":80},{"nctId":"NCT00358930","phase":"PHASE2","title":"A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2006-07","conditions":"Head and Neck Neoplasms, Carcinoma, Squamous Cell","enrollment":60},{"nctId":"NCT00099190","phase":"PHASE1","title":"ARQ 501 in Combination With Docetaxel in Patients With Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2004-12","conditions":"Carcinoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARQ 501","genericName":"ARQ 501","companyName":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","companyId":"arqule-inc-a-subsidiary-of-merck-sharp-dohme-llc-a-subsidiary-of-merck-co-inc-ra","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. Used for Non-small cell lung cancer with ALK rearrangement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}